Skip to main content
. 2022 Mar 26;14(7):1696. doi: 10.3390/cancers14071696

Figure 5.

Figure 5

Waterfall plots of individual relative changes in (A) non-normalized total lesion PSMA (TLP), (B) liver-normalized TLP (TLP-LR) and (C) parotid-normalized TLP (TLP-PR) after medication with enzalutamide. Black—enzalutamide-naïve patients. Grey—patients with previous enzalutamide treatment. Values over 100% were cropped for simplification.